TY - JOUR
T1 - Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety
AU - Duszynski, Katherine M.
AU - Stark, James H.
AU - Cohet, Catherine
AU - Huang, Wan Ting
AU - Shin, Ju Young
AU - Lai, Edward Chia Cheng
AU - Man, Kenneth K.C.
AU - Choi, Nam Kyong
AU - Khromava, Alena
AU - Kimura, Tomomi
AU - Huang, Kui
AU - Watcharathanakij, Sawaeng
AU - Kochhar, Sonali
AU - Chen, Robert T.
AU - Pratt, Nicole L.
N1 - Funding Information:
The authors acknowledge the participation and contribution of survey respondents from Australia, China, Hong Kong, Japan, Republic of Korea, Malaysia, New Zealand, Philippines, Singapore, Thailand, Taiwan and Vietnam. Funding to support this manuscript development was provided by the International Society for Pharmacoepidemiology (ISPE). This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE). NP and KMD were supported by an Australian Government National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Post-Marketing Surveillance of Medicines and Medical Devices grant (GNT1040938) and NHMRC Project Grant (GNT1157506). The funders played no role in the analysis or interpretation of the data or in the preparation of this manuscript. No financial support was received by any of the authors for the work reported on in the manuscript.
Publisher Copyright:
© 2021 John Wiley & Sons Ltd.
PY - 2021/7
Y1 - 2021/7
N2 - Introduction: Information regarding availability of electronic healthcare databases in the Asia-Pacific region is critical for planning vaccine safety assessments particularly, as COVID-19 vaccines are introduced. This study aimed to identify data sources in the region, potentially suitable for vaccine safety surveillance. This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE). Methods: Nineteen countries targeted for database reporting were identified using published country lists and review articles. Surveillance capacity was assessed using two surveys: a 9-item introductory survey and a 51-item full survey. Survey questions related to database characteristics, covariate and health outcome variables, vaccine exposure characteristics, access and governance, and dataset linkage capability. Other questions collated research/regulatory applications of the data and local publications detailing database use for research. Results: Eleven databases containing vaccine-specific information were identified across 8 countries. Databases were largely national in coverage (8/11, 73%), encompassed all ages (9/11, 82%) with population size from 1.4 to 52 million persons. Vaccine exposure information varied particularly for standardized vaccine codes (5/11, 46%), brand (7/11, 64%) and manufacturer (5/11, 46%). Outcome data were integrated with vaccine data in 6 (55%) databases and available via linkage in 5 (46%) databases. Data approval processes varied, impacting on timeliness of data access. Conclusions: Variation in vaccine data availability, complexities in data access including, governance and data release approval procedures, together with requirement for data linkage for outcome information, all contribute to the challenges in building a distributed network for vaccine safety assessment in the Asia-Pacific and globally. Common data models (CDMs) may help expedite vaccine safety research across the region.
AB - Introduction: Information regarding availability of electronic healthcare databases in the Asia-Pacific region is critical for planning vaccine safety assessments particularly, as COVID-19 vaccines are introduced. This study aimed to identify data sources in the region, potentially suitable for vaccine safety surveillance. This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE). Methods: Nineteen countries targeted for database reporting were identified using published country lists and review articles. Surveillance capacity was assessed using two surveys: a 9-item introductory survey and a 51-item full survey. Survey questions related to database characteristics, covariate and health outcome variables, vaccine exposure characteristics, access and governance, and dataset linkage capability. Other questions collated research/regulatory applications of the data and local publications detailing database use for research. Results: Eleven databases containing vaccine-specific information were identified across 8 countries. Databases were largely national in coverage (8/11, 73%), encompassed all ages (9/11, 82%) with population size from 1.4 to 52 million persons. Vaccine exposure information varied particularly for standardized vaccine codes (5/11, 46%), brand (7/11, 64%) and manufacturer (5/11, 46%). Outcome data were integrated with vaccine data in 6 (55%) databases and available via linkage in 5 (46%) databases. Data approval processes varied, impacting on timeliness of data access. Conclusions: Variation in vaccine data availability, complexities in data access including, governance and data release approval procedures, together with requirement for data linkage for outcome information, all contribute to the challenges in building a distributed network for vaccine safety assessment in the Asia-Pacific and globally. Common data models (CDMs) may help expedite vaccine safety research across the region.
KW - Asia-Pacific
KW - electronic medical records
KW - healthcare database
KW - safety
KW - surveillance
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85102896499&partnerID=8YFLogxK
U2 - 10.1002/pds.5214
DO - 10.1002/pds.5214
M3 - Article
C2 - 33634545
AN - SCOPUS:85102896499
VL - 30
SP - 843
EP - 857
JO - Pharmacoepidemiology and Drug Safety
JF - Pharmacoepidemiology and Drug Safety
SN - 1053-8569
IS - 7
ER -